![PitchBook a Morningstar company logo RGB-white.png](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="150" height="41"><rect fill-opacity="0"/></svg>){kind=small}
Formation Bio Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
180
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$372M
- Investors
-
27
Formation Bio General Information
Description
Developer of a biotech investment and development platform intended to accelerate drug development. The company's platform utilizes AI-driven technologies, customized workflow enhancements, strategic acquisition of clinical-stage assets, adaptable licensing structures, and integrated expert teams, enabling pharma partners and research institutions to advance treatments more efficiently while reducing cost, time, and development risk.
Contact Information
Website
www.formation.bioCorporate Office
- 16 East 34th Street
- Floor 10
- New York, NY 10016
- United States
Formation Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series D) | 26-Jun-2024 | $372M | Completed | Clinical Trials - Phase 3 | ||
| 5. Later Stage VC (Series C) | 30-Sep-2021 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series B) | 15-Oct-2018 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series A) | 31-Aug-2017 | Completed | Clinical Trials - Phase 3 | |||
| 2. Seed Round | 06-Jul-2016 | $2.3M | $2.32M | Completed | Clinical Trials - Phase 3 | |
| 1. Accelerator/Incubator | 01-Jan-2016 | $25K | $25K | Completed | Clinical Trials - Phase 3 |
Formation Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | 26,243,120 | $0.000001 | $0.05 | $0.58 | $0.58 | 1x | $0.58 | 12.63% |
| Seed | 19,490,650 | $0.000001 | $0.01 | $0.12 | $0.12 | 1x | $0.12 | 9.38% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Formation Bio Comparisons
Industry
Financing
Details
Formation Bio Competitors (5)
One of Formation Bio’s 5 competitors is InSilico Medicine Cayman, a Formerly VC-backed company based in Hong Kong, Hong Kong.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InSilico Medicine Cayman | Formerly VC-backed | Hong Kong, Hong Kong | ||||
| Enveda | Venture Capital-Backed | Boulder, CO | ||||
| CTI Clinical Trial and Consulting | Private Equity-Backed | Covington, KY | ||||
| Profluent | Venture Capital-Backed | Emeryville, CA | ||||
| Xaira Therapeutics | Venture Capital-Backed | South San Francisco, CA |
Formation Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Formation Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Formation Bio Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andreessen Horowitz | Venture Capital | Minority | ||
| Bridgespan VC | Venture Capital | Minority | ||
| FPV Ventures | Venture Capital | Minority | ||
| LTS Growth | Growth/Expansion | Minority | ||
| Northstar.VC | Venture Capital | Minority |
Formation Bio Investments (3)
Formation Bio’s most recent deal was a Corporate Asset Purchase with Asana BioSciences (Portfolio of Immunodermatology Assets). The deal was made on 29-Nov-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Asana BioSciences (Portfolio of Immunodermatology Assets) | 29-Nov-2022 | Corporate Asset Purchase | Buildings and Property | ||
| January (Financial Software) | 30-Mar-2022 | Later Stage VC | Financial Software | ||
| Merck Group (global rights to Sprifermin) | 01-Jan-2022 | Corporate Asset Purchase | Buildings and Property |
Formation Bio FAQs
-
When was Formation Bio founded?
Formation Bio was founded in 2013.
-
Where is Formation Bio headquartered?
Formation Bio is headquartered in New York, NY.
-
What is the size of Formation Bio?
Formation Bio has 180 total employees.
-
What industry is Formation Bio in?
Formation Bio’s primary industry is Drug Discovery.
-
Is Formation Bio a private or public company?
Formation Bio is a Private company.
-
What is the current valuation of Formation Bio?
The current valuation of Formation Bio is .
-
What is Formation Bio’s current revenue?
The current revenue for Formation Bio is .
-
How much funding has Formation Bio raised over time?
Formation Bio has raised $619M.
-
Who are Formation Bio’s investors?
Andreessen Horowitz, Bridgespan VC, FPV Ventures, LTS Growth, and Northstar.VC are 5 of 27 investors who have invested in Formation Bio.
-
Who are Formation Bio’s competitors?
InSilico Medicine Cayman, Enveda, CTI Clinical Trial and Consulting, Profluent, and Xaira Therapeutics are competitors of Formation Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process